Research Articles
Published research studies are articles that present the findings of original research that has undergone a peer-review process and has been made publicly available in scholarly journals, books or other media.
How to submit an article:
- Registered users can submit any published journal article that has a unique DOI (Digital Object Identifier) name or link to Research Hub.
- For example, you can paste the full DOI link:
https://doi.org/10.1109/5.771073 or just the DOI name: 10.1109/5.771073 into the field above and click submit.
- The person who is first to submit a valid article to Research Hub will forever be credited for it, and every article submission earns you +6 Research Points.
Research Insights
Insights are moderated by the Research Hub team and offer an at-a-glance overview of interesting research findings.
HuoXiang ZhengQi (HQXXD) may be a safe and effective treatment for Chronic Cough Variant Asthma (CVA), improving clinical efficacy and airway responsiveness while reducing recurrence rates.
Systematic Review Asthma Cough Huang Qi
HuoXiang ZhengQi (HQXXD) for Chronic Cough Variant Asthma (CVA) was systematically evaluated. The HQXXD group showed significantly higher total effective rates of clinical efficacy and airway responsiveness compared to the control group, while the recurrence rate was lower. Adverse reactions were not reported in HQXXD treatment, indicating its safety for CVA patients.
View Article
Review Articles
Review articles summarise and critically evaluate the current state of research on a specific topic or field by synthesising multiple primary research studies.
Clinical Trials
Clinical trials are research studies that involve people and are conducted to evaluate the safety and efficacy of new treatments or interventions, such as drugs, medical devices, or behavioural therapies.
Study Protocols
Published study protocols are detailed plans that outline the objectives, methodology, statistical analyses, and organisation of a research study that have been made publicly available for others to review and use as a reference.
Presentation Slides
Chinese Medicine Research Hub
Systematic Review
HuoXiang ZhengQi (HQXXD) may be a safe and effective treatment for Chronic Cough Variant Asthma (CVA), improving clinical efficacy and airway responsiveness while reducing recurrence rates.
2022 Evidence-Based Complementary and Alternative Medicine The Effectiveness and Safety of Huangqi Xixin Decoction for Cough Variant Asthma: A Systematic Review and Meta-Analysis
Wang C, Xia Q, Hu B, Jiang W, Zhang H
Executive Summary
Write an executive summary in the form of a blog article on the topic of "Research into Chinese medicine treatment for Huangqi Xixin decoction" summarising the research below and using language that can be easily understood by patients and avoiding medical jargon using a professional and caring tone of voice.
Write an executive summary in the form of a blog article on the topic of "Researched Chinese medicine treatments for Huangqi Xixin decoction" summarising the research below in an objective and easy to understand way, and using language that can be easily understood by patients. Group the article into Chinese medicine treatments first, followed by nutrition and other treatments. Avoid using medical jargon and use a professional and caring tone of voice.
Write me a concise but easy to understand executive summary on the topic of "Chinese medicine treatments for Huangqi Xixin decoction" based on the following research that I will give you. Your summary should be 2 paragraphs long in Australian English spelling and include references to the studies.
A Systematic Review published in 2022 in the journal Evidence-Based Complementary and Alternative Medicine found that HuoXiang ZhengQi (HQXXD) may be a safe and effective treatment for Chronic Cough Variant Asthma (CVA), improving clinical efficacy and airway responsiveness while reducing recurrence rates. HuoXiang ZhengQi (HQXXD) for Chronic Cough Variant Asthma (CVA) was systematically evaluated. The HQXXD group showed significantly higher total effective rates of clinical efficacy and airway responsiveness compared to the control group, while the recurrence rate was lower. Adverse reactions were not reported in HQXXD treatment, indicating its safety for CVA patients.
Sign In
Users not signed in are limited to viewing the 5 most recent items of content.
Sign In
Create Account
Share Huangqi Xixin decoction
HuoXiang ZhengQi (HQXXD) may be a safe and effective treatment for Chronic Cough Variant Asthma (CVA), improving clinical efficacy and airway responsiveness while reducing recurrence rates.